Study of Tarceva and Targretin in Stage I-II Lung Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and
Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by
the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the
treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.